In contrast, there are currently four approved small molecule inhibitors of PARP-1, namely, Olaparib, rucaparib, talazoparib, and niraparib, which target PARP-1′s function and activity at the protein level and are used for several forms of cancer [92]. This evidence concerns the gene PARP1 and cancer.